Healthcare / BiotechnologyNasdaqGS
$4.53
-0.16 (-3.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-166.0M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$316M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.9%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+56.1%
FCF CAGR
—
FCF margin
-347.2%
FCF / Net income
1.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $72.6M · net income $-219.0M · FCF $-252.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $72.6M | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M | $7.1M | $2.1M |
| Net Income | $-219.0M | $-219.0M | $-169.0M | $-180.7M | $-112.7M | $-66.8M | $-51.0M | $-30.6M | $-21.8M | $-16.3M |
| EBITDA | $-212.2M | $-212.2M | $-164.9M | $-169.4M | $-107.2M | $-64.2M | $-50.7M | $-25.3M | $-21.0M | $-15.9M |
| EPS | -3.16 | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | — | — |
| Operating Margin | -341.3% | -341.3% | -592.9% | -704.1% | -806.6% | -561.0% | -500.1% | -190.6% | -304.7% | -787.0% |
| Net Margin | -301.7% | -301.7% | -479.2% | -669.7% | -779.3% | -571.2% | -491.0% | -221.8% | -306.1% | -789.3% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.03 | 0.03 | 0.01 | 0.12 | 0.16 | 0.09 | 0.15 | — | — | — |
| Current Ratio | 12.66 | 12.66 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-252.0M | $-252.0M | $-166.0M | $-63.6M | $-105.1M | $-16.8M | $-19.0M | $-30.2M | $-27.3M | $-2.5M |
| Returns | ||||||||||
| ROE | -35.9% | -35.9% | -21.3% | -48.7% | -41.6% | -19.3% | -53.4% | -32.8% | 31.3% | 34.5% |
| Valuation | ||||||||||
| P/B | 0.51 | 0.51 | 1.09 | 1.64 | 3.44 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 105.8% | 105.8% | 30.8% | 86.5% | — | 12.6% | -24.7% | 93.4% | 246.4% | — |
| EPS Growth | -9.0% | -9.0% | 42.9% | -33.7% | — | -0.4% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.90 → -3.16
Residual
-44.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.